Untreated Chemotherapy-induced neutropenia (CIN) comes at a price
The cascading negative effects of untreated CIN can be seen in ER visits as well as repeated and extended hospitalizations. These effects may lead to further and severe health complications, including both infection and sepsis.1
CIN impacts both finances and resources
CIN drains both practice productivity and healthcare resources. Related hospitalizations not only result in medical costs but also may increase the chances of morbidity and mortality.2
The numbers for patient hospitalizations for CIN are staggering:
5.1
The average number of days per stay3
$63,245
WHAT A COST PER STAY COULD REACH4
CIN accounts for approximately 110,000 hospitalizations annually and
Expert Perspectives in CIN
Video Transcript
Dr. Lyman: The cost side of this is not just the growth factor itself, but it’s what you’re trying to prevent, which is hospitalization. The cost of hospitalization has gone up enormously in the United States over the last decade or decade and a half. So, every day the patient’s in the hospital, the cost that may come to their insurance company, but increasingly is being passed on because of caps or copays, to the patients themselves. Then patients with less than optimal insurance may end up with tens or hundreds of thousands of dollars’ worth of bills from a single hospitalization. So, we want to prevent these costly and serious life-threatening complications as best as possible.
#CINSIGHTS
WHEN IT COMES TO THE TIMELY PREVENTION OF CIN, INNOVATION IS ON THE HORIZON.
References:
- Gupta A, Abbasi B, Gupta S. Management of chemotherapy induced neutropenia—an unmet clinical need. Am J Biomed Sci & Res. 2019;4(5):313-318.
- Tai E, Guy GP, Dunbar A, Richardson LC. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e561-e561.
- Healthcare Cost and Utilization Project (HCUP). 2017. Agency for Healthcare Research and Quality, Rockville, MD. Accessed November 13, 2020. https://hcupnet.ahrq.gov
- Epstein R, et al. Real-world burden of myelosuppression in patients with small cell lung cancer (SCLC): retrospective, longitudinal data analysis. 2020 ASCO Virtual Scientific Program. Abstract e19300.
